DE3854125D1 - VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN. - Google Patents

VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN.

Info

Publication number
DE3854125D1
DE3854125D1 DE3854125T DE3854125T DE3854125D1 DE 3854125 D1 DE3854125 D1 DE 3854125D1 DE 3854125 T DE3854125 T DE 3854125T DE 3854125 T DE3854125 T DE 3854125T DE 3854125 D1 DE3854125 D1 DE 3854125D1
Authority
DE
Germany
Prior art keywords
improved method
factor viii
type proteins
producing factor
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3854125T
Other languages
English (en)
Other versions
DE3854125T2 (de
DE3854125T3 (de
Inventor
Randal Kaufman
S Adamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26711519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3854125(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE3854125D1 publication Critical patent/DE3854125D1/de
Publication of DE3854125T2 publication Critical patent/DE3854125T2/de
Application granted granted Critical
Publication of DE3854125T3 publication Critical patent/DE3854125T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE3854125T 1987-04-06 1988-04-06 VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN. Expired - Lifetime DE3854125T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3488287A 1987-04-06 1987-04-06
US6886587A 1987-07-02 1987-07-02
PCT/US1988/001114 WO1988008035A1 (en) 1987-04-06 1988-04-06 IMPROVED METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS

Publications (3)

Publication Number Publication Date
DE3854125D1 true DE3854125D1 (de) 1995-08-10
DE3854125T2 DE3854125T2 (de) 1996-01-04
DE3854125T3 DE3854125T3 (de) 2000-10-12

Family

ID=26711519

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3854125T Expired - Lifetime DE3854125T3 (de) 1987-04-06 1988-04-06 VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN.

Country Status (6)

Country Link
EP (1) EP0362218B2 (de)
JP (1) JPH02503744A (de)
AT (1) ATE124725T1 (de)
CA (1) CA1331157C (de)
DE (1) DE3854125T3 (de)
WO (1) WO1988008035A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US6475787B1 (en) 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
US7247475B2 (en) 1989-07-28 2007-07-24 Wyeth Method for producing monoclonal antibodies
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
AU6486196A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
JP3987114B2 (ja) 1996-04-24 2007-10-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 不活性化耐性第▲８▼因子
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
ATE222925T1 (de) 1998-03-12 2002-09-15 Inst Genetics Llc Verbessertes verfahren zur herstellung von faktor viii
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
EP1351986A2 (de) 2001-01-12 2003-10-15 The American National Red Cross Verfahren und zusammensetzungen zur verminderung von heparansulfatproteoglykan-vermittelter entfernung von faktor viii
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
AU2007269233B2 (en) 2006-06-30 2011-06-09 Cnj Holdings, Inc. Method of producing Factor VIII proteins by recombinant methods
EP1988101A1 (de) 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
EP3508573A1 (de) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
ES2556454T3 (es) 2010-10-05 2016-01-18 Novo Nordisk Health Care Ag Proceso para producción de proteínas
EP2717898B1 (de) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Gerinnungsfördernde verbindungen und anwendungsverfahren dafür
EA029045B1 (ru) 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
KR102212098B1 (ko) 2012-01-12 2021-02-03 바이오버라티브 테라퓨틱스 인크. 키메라 인자 viii 폴리펩티드들과 이의 용도
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
SG11201404885RA (en) 2012-02-15 2014-09-26 Amunix Operating Inc Factor viii compositions and methods of making and using same
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
EP2870250B2 (de) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
SG11201500045RA (en) 2012-07-11 2015-02-27 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (de) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
EA201890671A1 (ru) 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
CN113831415A (zh) 2013-06-28 2021-12-24 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
EP3875106A1 (de) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
BR112016015512B1 (pt) 2014-01-10 2023-12-19 Bioverativ Therapeutics Inc Proteína quimérica, composição farmacêutica e seus usos
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813389A (ja) * 1981-07-16 1983-01-25 Kyowa Hakko Kogyo Co Ltd 細胞培養用培地
JPS5823784A (ja) * 1981-08-04 1983-02-12 Ajinomoto Co Inc 哺乳動物細胞用培地
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
EP0162067B1 (de) * 1983-10-28 1992-07-15 Genetics Institute, Inc. Herstellung des faktors viii und damit verwandte erzeugnisse
WO1987004187A1 (en) * 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
WO1988005825A1 (en) * 1987-01-30 1988-08-11 Biogen N.V. A method for producing factor viii in high yield

Also Published As

Publication number Publication date
EP0362218A1 (de) 1990-04-11
EP0362218B2 (de) 2000-04-12
JPH02503744A (ja) 1990-11-08
EP0362218B1 (de) 1995-07-05
WO1988008035A1 (en) 1988-10-20
ATE124725T1 (de) 1995-07-15
CA1331157C (en) 1994-08-02
DE3854125T2 (de) 1996-01-04
EP0362218A4 (en) 1990-09-19
DE3854125T3 (de) 2000-10-12

Similar Documents

Publication Publication Date Title
DE3854125D1 (de) VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN.
DE3785102T2 (de) Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
DE3752372D1 (de) Verfahren zur regulierung der metabolischen stabilität von proteinen
DE59608743D1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
DE69637867D1 (de) Verfahren zur Kontrollierung der Sialylierung von durch Säugetierzellkultur hergestellten Proteinen
DE3280479D1 (de) Rekombinante DNS-Mittel und Verfahren
DE59610898D1 (de) Verfahren zur herstellung von erythropoietin frei von tierischen proteinen
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
FI852547L (fi) Framstaellning av faktor viii och daertill hoerande produkter.
DE3587422T2 (de) Für ein hirudinähnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
DE3862306D1 (de) Verfahren zur elektrochemischen herstellung von carbonsaeuren.
DE69430975T2 (de) Verfahren zur Herstellung von Proteinen
DE3886292D1 (de) Expressionsvektoren und Verfahren unter deren Verwendung zur Gewinnung von Cro/beta-Galaktosidase/PTH-Fusionsproteinen und von PTH.
DE69425809T2 (de) Methoden zur Herstellung von Protein C
DE68926922D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren
AT387906B (de) Verfahren zur herstellung von biologisch vertraeglichen materialien
ATE125298T1 (de) Verfahren zur herstellung von motilinähnlichen polypeptiden und seine expression.
DE3678552D1 (de) Verfahren zur herstellung von proteinen unter verwendung von transformierten milchsaeurebakterien.
DE3884261D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten.
DE3677421D1 (de) Mikrobiologisches verfahren zur herstellung von menschlichem lysozym.
DE3782350D1 (de) Rekombinante parvovirus-ra-1-produkte und verfahren zu deren anwendung.
DE3574967D1 (de) Verfahren zur herstellung von 3-(4-fluorphenoxy)-propionitril und verfahren zur herstellung von 6-fluor-4-chromanon unter verwendung von 3-(4-fluorphenoxy)-propionitril.
ATE110775T1 (de) Verfahren zur herstellung von hirudin.
DE58909205D1 (de) Expressionsvektor und Verfahren zur regulierbaren Herstellung von Proteinen in Eukaryonten.
ATE71145T1 (de) Expressionsvektoren, solche vektoren enthaltende wirtszellen und verfahren zur herstellung gewuenschter produkte unter verwendung solcher zellen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US